Genentech announces results from pertuzumab studies on HER2-positive breast cancer
Genentech, a member of the Roche Group, today announced the company will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10.
More... |
Re: Genentech announces results from pertuzumab studies on HER2-positive breast cance
I was just wondering, if pertuzumab get approved, it will be approved for second line and beyond as well?
|
All times are GMT -7. The time now is 07:37 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021